MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Thermo Fisher Scientific Accounts Payables 2011-2026 | TMO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Thermo Fisher Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.08 B | 2.87 B | 3.38 B | 2.87 B | 2.18 B | 1.92 B | 1.62 B | 1.43 B | 926 M | 822 M | 821 M | 692 M | 641 M | 612 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.38 B | 612 M | 1.7 B |
Quarterly Accounts Payables Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.12 B | 2.98 B | 3.05 B | 2.61 B | 2.55 B | 2.56 B | 2.51 B | 2.42 B | 2.8 B | 3.38 B | 2.47 B | - | 2.67 B | 2.87 B | 2.3 B | 2.1 B | 2.15 B | 2.18 B | 2.18 B | 2.18 B | 2.18 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.62 B | 1.62 B | 1.62 B | 1.62 B | 1.43 B | 1.43 B | 1.43 B | 1.43 B | 926 M | 926 M | 926 M | 926 M | 822 M | 822 M | 822 M | 822 M | 821 M | 821 M | 821 M | 821 M | 692 M | 692 M | 692 M | 692 M | 641 M | 641 M | 641 M | 641 M | 612 M | 612 M | 612 M | 629 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.38 B | 612 M | 1.59 B |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
6.96 M | $ 1.16 | 3.12 % | $ 1.47 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 26.8 | -3.0 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | USA |
 |
Celcuity
CELC
|
9.37 M | $ 108.23 | 2.31 % | $ 4.27 B | USA |
 |
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M |  Israel |
 |
Danaher Corporation
DHR
|
1.84 B | $ 209.64 | 0.22 % | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
1.13 M | $ 11.26 | - | $ 319 M | Israel |
 |
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
18.4 M | $ 23.42 | 1.43 % | $ 708 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
287 M | $ 209.3 | -0.11 % | $ 23.2 B | USA |
 |
Castle Biosciences
CSTL
|
6.9 M | $ 30.44 | 1.67 % | $ 846 M | USA |
 |
CareDx, Inc
CDNA
|
12.9 M | $ 17.63 | -8.42 % | $ 948 M | USA |
 |
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
344 M | $ 72.79 | -0.41 % | $ 28.4 B | USA |
 |
Interpace Biosciences
IDXG
|
1.66 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
176 M | $ 103.39 | -0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
841 M | $ 285.93 | -0.42 % | $ 23.8 B | USA |
 |
Guardant Health
GH
|
54.4 M | $ 95.36 | -0.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
149 M | $ 170.5 | 2.67 % | $ 8.45 B | USA |
 |
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
30 M | $ 4.61 | 4.06 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
173 M | $ 103.45 | -0.61 % | $ 8.53 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
270 K | $ 3.5 | -9.32 % | $ 1.88 M | USA |
 |
IDEXX Laboratories
IDXX
|
110 M | $ 660.2 | 1.69 % | $ 53.1 B | USA |
 |
Illumina
ILMN
|
221 M | $ 123.23 | 0.26 % | $ 19.6 B | USA |
 |
Natera
NTRA
|
31.1 M | $ 209.8 | 0.13 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
322 M | $ 163.11 | -1.07 % | $ 28 B | USA |
 |
Mettler-Toledo International
MTD
|
267 M | $ 1 375.3 | -0.28 % | $ 28.3 B |  Schweiz |
 |
Pacific Biosciences of California
PACB
|
15.1 M | $ 1.7 | 2.11 % | $ 431 M | USA |
|
Biodesix
BDSX
|
2.19 M | $ 13.3 | 2.15 % | $ 1.72 B | USA |
 |
Lantheus Holdings
LNTH
|
34.6 M | $ 74.86 | 1.7 % | $ 5.18 B | USA |
 |
Biomerica
BMRA
|
295 K | $ 2.1 | - | $ 4.82 M | USA |